Evaluation of multi-inflammatory ındexes in persons living with human immunodeficiency virus: a multicenter study

The aim of the study was to evaluate inflammatory markers after 1 year of antiretroviral therapies use in persons living with human immunodeficiency virus.

This is a retrospective, observational, and multicenter study. The study included adult, comorbid disease-free patients who received antiretroviral therapies with a diagnosis of human immunodeficiency virus infection. Multi-inflammatory index, multi-inflammatory index obtained by various formulations of complete blood count, C-reactive protein, neutrophil count, lymphocyte count, and platelet count, systemic immune-inflammatory index, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, C-reactive protein/lymphocyte ratio, cluster of differentiation 4 (CD4) T lymphocyte percentage, and CD4/CD8 ratio data were compared with pretreatment data.

A total of 391 persons living with human immunodeficiency virus, including 241 (61.6%) women, were included in the study. When pretreatment human immunodeficiency virus ribonucleic acid, neutrophil count, lymphocyte count, platelet count, C-reactive protein level, CD4 percentage, CD8 percentage, CD4/CD8 ratio, multi-inflammatory index-1, multi-inflammatory index-2, and systemic immune-inflammatory index data were compared with the 48th week of treatment, a statistically significant difference was found except for neutrophils (p<0.05). When the 48th week post-treatment data were evaluated, human immunodeficiency virus ribonucleic acid, C-reactive protein, multi-inflammatory index-1, multi-inflammatory index-2, and systemic immune-inflammatory index values decreased; lymphocyte, platelet, CD4, CD8, and CD4/CD8 ratio values increased. Among the pretreatment markers, systemic immune-inflammatory index, platelet/lymphocyte ratio, and neutrophil/lymphocyte ratio predicted CD4/CD8 ratio ≤1 or >1 at the end of 48 weeks at the highest rate (60.7, 60, and 59.6%, respectively).

Multi-inflammatory markers were found to regress after antiretroviral therapies use in persons living with human immunodeficiency virus. In the long term, these patients should be monitored for the effects of chronic inflammation.